New drug watch: ADZYNMA under microscope for rare TTP patients
NCT ID NCT06441578
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 27 times
Summary
This study tracks the safety of a drug called ADZYNMA in 40 people with a rare blood disorder (congenital TTP) in Japan. Doctors will monitor side effects and check if the drug helps prevent or treat TTP episodes over 18 months. Participants receive the drug as part of their normal care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.